ĐÁNH GIÁ KẾT QUẢ HÓA TRỊ TÂN HỖ TRỢ KẾT HỢP TRASTUZUMAB ĐIỀU TRỊ BỆNH NHÂN UNG THƯ VÚ GIAI ĐOẠN II-III TẠI BỆNH VIỆN UNG BƯỚU THÀNH PHỐ HỒ CHÍ MINH

Abstract

Background: Breast cancer is the most common cause of death among women. Consequently, multimodal treatment has been studied, researched, and developed such as surgery, chemotherapy, endocrine therapy, radiotherapy, targeted therapy, and immunotherapy. Trastuzumab is the first-line anti-Her-2 monoantibody for positive Her-2 receptor breast cancer patients. Objectives: To evaluate the efficacy of neoadjuvant chemotherapy combined with trastuzumab in stage II-III breast cancer female patients. Materials and methods: Cross-sectional descriptive study on 111 patients with Her2 positive breast cancer stages II-III prescribed: trastuzumab, docetaxel, carboplatin regimen at Ho Chi Minh Oncology Hospital  from January 2022 to the end of March 2024. Results: The average age of the study was 49 years old. The majority of patients in the study were in stage IIIB. Treatment results was satisfactory and toxicities were minimal. The total pathological complete response (tpCR ) rate reached 44.1%, of which tumor pathological complete response accounted for 55.9% and lymph node pathological complete response accounted for 64%. Conclusion: Neoadjuvant chemotherapy combined with trastuzumab increases patholological complete response rate and disease downstage dramatically, ensures efficacy for mastectomy and breast-conserving surgery.